In today’s briefing:
- Orum Therapeutics Lowers IPO Price Range
- CTSO: CytoSorbents reports preliminary 4th quarter and 2024 financial results which showed impressive growth in the core international business that exceeded our expectations.
- Masimo Corporation: Here Are the 6 Most Critical Factors Shaping Its Performance in 2025 & Beyond! – Major Drivers
- Neurocrine Biosciences: Commercial Expansion & Market Penetration Underpinning Our ‘Outperform’ Rating! – Major Drivers
- Seres Therapeutics: Will Its Strategic Partnerships & Collaborations Prove to Be a Game-Changing Move?
- Stevanato Group: Engineering Optimization For A Competitive Edge But Will It Work? – Major Drivers
Orum Therapeutics Lowers IPO Price Range
- Orum Therapeutics (475830 KS) has lowered its IPO price range to 24,000 won to 30,000 won.
- The IPO offering amount will be between 60 billion won to 75 billion won. The expected market cap of the IPO is between 531 billion won to 664 billion won.
- Our updated valuation of Orum Therapeutics suggests implied target price of 24,939 won per share, which is 8% lower than the mid-point of the revised down IPO price range.
CTSO: CytoSorbents reports preliminary 4th quarter and 2024 financial results which showed impressive growth in the core international business that exceeded our expectations.
- CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive care unit and cardiac surgery.
- The company also seeks U.S. and Canadian approval of a second product, DrugSorb-ATR, to reduce perioperative bleeding risk in patients on blood thinners during cardiac surgery.
- Based on the results of its pivotal U.S. and Canadian STAR-T trial, the company submitted for FDA De Novo approval on September 27, 2024, and Health Canada on November 1, 2024, with regulatory decisions expected in 2025.
Masimo Corporation: Here Are the 6 Most Critical Factors Shaping Its Performance in 2025 & Beyond! – Major Drivers
- Masimo Corporation, a global technology company focused on experienced healthcare solutions, recently reported its financial results for the third quarter of 2024.
- The company’s healthcare segment demonstrated robust performance, with revenues reaching $343 million, showcasing a 12% year-over-year growth.
- This growth was attributed to increased consumable and service revenues, although partially offset by a decline in capital equipment sales.
Neurocrine Biosciences: Commercial Expansion & Market Penetration Underpinning Our ‘Outperform’ Rating! – Major Drivers
- Neurocrine Biosciences has presented its third-quarter 2024 results, highlighting both achievements and ongoing strategic initiatives.
- Under the new leadership of CEO Kyle Gano, the company is focusing on strengthening its position as a leading neuroscience organization.
- Its revenue growth has been particularly driven by the performance of its drug INGREZZA, with an impressive $613 million in sales this quarter, translating to 25% year-over-year growth.
Seres Therapeutics: Will Its Strategic Partnerships & Collaborations Prove to Be a Game-Changing Move?
- Seres Therapeutics has outlined significant developments and strategic decisions during its third-quarter 2024 update.
- The company achieved notable milestones, primarily around its lead clinical candidate, SER-155, and its corporate financial structure, significantly influenced by the sale of its VOWST program to Nestlé Health Science.
- Seres reported positive data from its Phase Ib clinical trial for SER-155, indicating a potential for reducing bacterial bloodstream infections (BSIs) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Stevanato Group: Engineering Optimization For A Competitive Edge But Will It Work? – Major Drivers
- Stevanato Group’s third-quarter 2024 financial results present a complex picture that warrants a balanced examination of both its organizational strategies and market dynamics.
- The company reported a modest 2% revenue growth year-over-year, slightly tempered by persistent challenges in its Engineering segment and vial destocking effects.
- These factors influenced management’s decision to lower the full-year 2024 guidance for adjusted EBITDA and adjusted diluted EPS.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
